NasdaqGS:GILDBiotechs
A Look at Gilead Sciences (GILD) Valuation After Landmark EU Approval for Twice-Yearly HIV Prevention Therapy
Gilead Sciences (GILD) just scored a major regulatory win: the European Commission has granted marketing authorization for lenacapavir, branded as Yeytuo. This makes it the first twice-yearly injectable PrEP option for HIV-1 prevention across the EU and select neighboring countries. This approval puts Gilead at the forefront of HIV prevention innovation and extends its reach into a market with substantial unmet need. The news follows recent FDA approval in the US and updated World Health...